Search results
- 21.03Add to watchlist-0.13 (-0.61%)At close: Mon. Jul 29, 2024 4:00 PM EDT · Delayed Quote (USD) · Pre-Market Time
- Open21.16High21.20Low20.95
- Mkt CapN/AP/E (TTM)8.85Div & Yield1.25 & 5.94%
- Prev. Close21.1652 Wk. Low18.2152 Wk. High22.80
Related stocks
Oct 6, 2023 · Tissue plasminogen activator (tPA) is a drug given through a vein to help break up a blood clot so that blood flow can return to normal. It is used for the emergency treatment of ischemic stroke, which occurs when a blood clot interrupts blood flow to a region of the brain. The timely administration of tPA can save lives.
Tissue-type plasminogen activator, short name tPA, is a protein that facilitates the breakdown of blood clots. It acts as an enzyme to convert plasminogen into its active form plasmin, the major enzyme responsible for clot breakdown. It is a serine protease ( EC 3.4.21.68) found on endothelial cells lining the blood vessels.
Feb 20, 2023 · Tissue plasminogen activator (tPA) is classified as a serine protease (enzymes that cleave peptide bonds in proteins). It is thus one of the essential components of the dissolution of blood clots.
- www.ninds.nih.gov
- › What We Do
Known by the generic name alteplase and marketed as Activase® (Genentech), tPA is given to patients through an IV in the arm, and it works by dissolving blood clots that block blood flow to the brain.
Alteplase, sold under the brand name Activase among others, is a biosynthetic form of human tissue-type plasminogen activator (t-PA). It is a thrombolytic medication used to treat acute ischemic stroke , acute ST-elevation myocardial infarction (a type of heart attack), pulmonary embolism associated with low blood pressure , and blocked central ...
Mar 28, 2023 · Tissue plasminogen activator (tPA) is a medication that doctors administer following a stroke caused by a blood clot. It breaks up the blood clot to allow blood flow to...
Mar 7, 2023 · Alteplase is a drug prescribed to treat conditions caused by arterial blood clots such as heart attacks, strokes, chest pain from unstable angina, and pulmonary embolism. The most common and serious side effect of alteplase is bleeding.
Mar 7, 2013 · Endovascular therapy is increasingly used after the administration of intravenous tissue plasminogen activator (t-PA) for patients with moderate-to-severe acute ischemic stroke, but whether a...
Jul 4, 2023 · Objectives: Identify the indications for initiating therapy with a tPA agent such as alteplase. Review the mechanism of action of tissue plasminogen activators such as alteplase. Summarize the contraindications and adverse event profile of tPA medications such as alteplase.
Dec 14, 1995 · We performed a randomized, double-blind trial of intravenous recombinant tissue plasminogen activator (t-PA) for ischemic stroke after recent pilot studies suggested that t-PA was...
